New Stock News | Sinovac Biotech submits Hong Kong Stock Exchange listing application with four clinical-stage proprietary drugs in its pipeline.

According to the Wise Finance and Economics APP, as disclosed by the Hong Kong Stock Exchange on November 12th, Zhejiang Shimai Pharmaceutical Co., Ltd.-B (hereinafter referred to as "Shimai Pharmaceutical") has submitted an application to the main board of the Hong Kong Stock Exchange, with Huatai International as its exclusive sponsor.